INVIVYD, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- INVIVYD, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $120.00K, a 53.85% increase year-over-year.
- INVIVYD, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $135.00K, a 206.82% increase year-over-year.
- INVIVYD, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $56.00K, a 107.41% increase year-over-year.
- INVIVYD, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $78.00K, a 4.00% increase year-over-year.
- INVIVYD, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $254.00K, a 13.90% increase from fiscal 2024.
- INVIVYD, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $223.00K, a 7.08% decline from fiscal 2023.
- INVIVYD, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $240.00K, a 10.78% decline from fiscal 2022.
- INVIVYD, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $269.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $120.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $135.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $254.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $56.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $78.00K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $44.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $223.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $27.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $75.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $89.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $240.00K 10-K · filed 2024-03-28 | |
| 2023-09-30 | $57.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $56.00K 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $83.00K 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $269.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $149.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |